Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.

Maryam EdalatifardMaryam AkhtariMohammadreza SalehiZohreh NaderiAhmadreza JamshidiShayan MostafaeiSeyed Reza NajafizadehElham FarhadiNooshin JaliliMasoud EsfahaniBesharat RahimiHossein KazemzadehMaedeh Mahmoodi AliabadiTooba GhazanfariMohammadreza SattarianHourvash Ebrahimi LouyehSeyed Reza RaeeskaramiSaeidreza JamalimoghadamsiahkaliNasim KhajaviradMahdi MahmoudiAbdolrahman Rostamian

Published in: The European respiratory journal (2020)

Our results suggest that methylprednisolone pulse could be an efficient therapeutic agent for hospitalised severe COVID-19 patients at the pulmonary phase.

Keyphrases

high dose
sars cov
clinical trial
blood pressure
coronavirus disease
early onset
study protocol
pulmonary hypertension
community acquired pneumonia
low dose
open label
drug induced
phase ii
respiratory syndrome coronavirus
placebo controlled